HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports.

Other research analysts have also issued reports about the stock. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $9.00 to $1.25 in a research report on Wednesday, January 29th.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.32 on Thursday. The business’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $2.17. Leap Therapeutics has a 52 week low of $0.31 and a 52 week high of $4.79. The firm has a market cap of $12.13 million, a price-to-earnings ratio of -0.16 and a beta of 0.35.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. As a group, equities research analysts forecast that Leap Therapeutics will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On Leap Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LPTX. Prosperity Wealth Management Inc. bought a new stake in Leap Therapeutics in the 4th quarter valued at $63,000. HighTower Advisors LLC bought a new stake in shares of Leap Therapeutics in the third quarter valued at about $65,000. Jane Street Group LLC bought a new stake in shares of Leap Therapeutics in the fourth quarter valued at about $107,000. Dauntless Investment Group LLC acquired a new stake in Leap Therapeutics during the fourth quarter worth about $144,000. Finally, NewEdge Advisors LLC increased its stake in Leap Therapeutics by 1,668,066.7% during the fourth quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock valued at $144,000 after acquiring an additional 50,042 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.